38.39 USD
-0.42 (-1.08%)
38.6316 USD
+0.24 (+0.63%)
Taking everything into account, RPRX scores 6 out of 10 in our fundamental rating. RPRX was compared to 191 industry peers in the Pharmaceuticals industry. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year RPRX was profitable.
In the past year RPRX had a positive cash flow from operations.
Each year in the past 5 years RPRX has been profitable.
RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RPRX has a better Return On Assets (3.95%) than 84.82% of its industry peers.
RPRX's Return On Equity of 11.93% is amongst the best of the industry. RPRX outperforms 86.39% of its industry peers.
The Return On Invested Capital of RPRX (6.43%) is better than 84.29% of its industry peers.
RPRX had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 12.85%.
The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
With an excellent Profit Margin value of 32.55%, RPRX belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
RPRX's Profit Margin has declined in the last couple of years.
RPRX has a Operating Margin of 65.22%. This is amongst the best in the industry. RPRX outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RPRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, RPRX has less shares outstanding
Compared to 5 years ago, RPRX has more shares outstanding
Compared to 1 year ago, RPRX has a worse debt to assets ratio.
2.2 Solvency
RPRX has an Altman-Z score of 1.66. This is a bad value and indicates that RPRX is not financially healthy and even has some risk of bankruptcy.
RPRX has a Altman-Z score (1.66) which is comparable to the rest of the industry.
The Debt to FCF ratio of RPRX is 9.47, which is on the high side as it means it would take RPRX, 9.47 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of RPRX (9.47) is better than 79.06% of its industry peers.
RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
RPRX has a worse Debt to Equity ratio (1.34) than 76.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.66 |
ROIC/WACC0.75
WACC8.61%
2.3 Liquidity
RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RPRX (3.48) is comparable to the rest of the industry.
RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 57.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.24% over the past year.
RPRX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.23% yearly.
The Revenue has been growing slightly by 3.70% in the past year.
Measured over the past years, RPRX shows a small growth in Revenue. The Revenue has been growing by 4.52% on average per year.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.58% on average per year.
RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.36% yearly.
EPS Next Y17.35%
EPS Next 2Y12.47%
EPS Next 3Y13.48%
EPS Next 5Y12.58%
Revenue Next Year15.78%
Revenue Next 2Y8.39%
Revenue Next 3Y8.23%
Revenue Next 5Y10.36%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.34, which indicates a very decent valuation of RPRX.
Based on the Price/Earnings ratio, RPRX is valued cheaper than 91.62% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.56. RPRX is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 7.40, the valuation of RPRX can be described as very cheap.
92.15% of the companies in the same industry are more expensive than RPRX, based on the Price/Forward Earnings ratio.
RPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.34 | ||
| Fwd PE | 7.4 |
4.2 Price Multiples
RPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RPRX is cheaper than 82.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.46 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RPRX may justify a higher PE ratio.
A more expensive valuation may be justified as RPRX's earnings are expected to grow with 13.48% in the coming years.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y12.47%
EPS Next 3Y13.48%
5. Dividend
5.1 Amount
RPRX has a Yearly Dividend Yield of 2.27%.
Compared to an average industry Dividend Yield of 0.52, RPRX pays a better dividend. On top of this RPRX pays more dividend than 93.19% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, RPRX pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.27% |
5.2 History
RPRX has been paying a dividend for over 5 years, so it has already some track record.
RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
49.36% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.47%
EPS Next 3Y13.48%
38.39
-0.42 (-1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.29%
Inst Owner Change-2.73%
Ins Owners1.82%
Ins Owner Change7.69%
Market Cap22.16B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts82.67
Price Target46 (19.82%)
Short Float %6.19%
Short Ratio6.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.27% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)3.71%
PT rev (3m)4.2%
EPS NQ rev (1m)-0.92%
EPS NQ rev (3m)2.51%
EPS NY rev (1m)4.99%
EPS NY rev (3m)4.79%
Revenue NQ rev (1m)1.83%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0.71%
Revenue NY rev (3m)1.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.34 | ||
| Fwd PE | 7.4 | ||
| P/S | 9.43 | ||
| P/FCF | 23.46 | ||
| P/OCF | 9.21 | ||
| P/B | 3.45 | ||
| P/tB | 4.04 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.71%
EPS(NY)5.19
Fwd EY13.51%
FCF(TTM)1.64
FCFY4.26%
OCF(TTM)4.17
OCFY10.85%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.54
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.66 |
F-Score5
WACC8.61%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y17.35%
EPS Next 2Y12.47%
EPS Next 3Y13.48%
EPS Next 5Y12.58%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year15.78%
Revenue Next 2Y8.39%
Revenue Next 3Y8.23%
Revenue Next 5Y10.36%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.71%
EBIT Next 3Y14.53%
EBIT Next 5Y13.57%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status of ROYALTY PHARMA PLC- CL A (RPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
Can you provide the profitability details for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.34 and the Price/Book (PB) ratio is 3.45.
Is the dividend of ROYALTY PHARMA PLC- CL A sustainable?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 5 / 10 and the dividend payout ratio is 49.36%.